
    
      This is a phase II study of bortezomib 1.3 mg/m^2 by intravenous pyelogram (IVP) on days 1,
      4, 8, and 11, vorinostat 180 mg/m^2 by mouth (PO) per day (not to exceed 400 mg per day) days
      1-14, and dexamethasone 6 mg/m^2 PO days 4-15 for the treatment of relapsed/refractory acute
      lymphoblastic leukemia (ALL). No more than 3 treatment courses may be given.
    
  